SCHEMBL21292370

SCHEMBL21292370

CC(C)(C)OC(=O)N1CCC(n2cc(B3OC(C)(C)C(C)(C)O3)c(F)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.44
DDB1 Q16531 1/20 0.42
CRBN Q96SW2 1/20 0.42
GPR119 Q8TDV5 5/20 0.39
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38
CTSD P07339 1/20 0.38
CTSE P14091 1/20 0.38
BACE1 P56817 1/20 0.38
TP53 P04637 1/20 0.37
DPP4 P27487 1/20 0.37
RECQL P46063 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPN6 P29350 1/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2385523 0.89 USP30 (0.45) USP30DDB1CRBNGPR119CCNC
SCHEMBL22900831 0.88 USP30 (0.43) USP30DDB1CRBNGPR119CCNC
SCHEMBL22532979 0.88 USP30 (0.49) USP30DDB1CRBNGPR119CCNC
SCHEMBL28927851 0.87 USP30 (0.44) USP30DDB1CRBNGPR119CCNC
SCHEMBL25209514 0.80 USP30 (0.44) USP30DDB1CRBNGPR119IRAK4
SCHEMBL30796398 0.80 USP30 (0.49) USP30DDB1CRBNGPR119CTSD
SCHEMBL25200273 0.80 IRAK4 (0.41) USP30IRAK4CTSDCTSEBACE1
SCHEMBL25373246 0.79 USP30 (0.46) USP30DDB1CRBNGPR119CTSD
SCHEMBL320828 0.79 USP30 (0.52) USP30DDB1CRBNGPR119CCNC
SCHEMBL17004842 0.79 USP30 (0.48) USP30DDB1CRBNGPR119CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539849-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
EP-3755696-B1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF BIOSPLICE THERAPEUTICS INC (US) 2023-04-05 EP disclosed
US-10934297-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof SAMUMED, LLC (US) 2021-03-02 US disclosed
US-20190263821-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934297-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, DYRK3 USP30 4750/4885DDB1 1363/4885CRBN 1500/4885
US-11713320-B2 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof DYRK1A, WNT3, DYRK3 USP30 4750/4885DDB1 1363/4885CRBN 1500/4885
US-20190263821-A1 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, WNT3, DYRK3 USP30 4750/4885DDB1 1363/4885CRBN 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.